血清胶质纤维酸性蛋白(GFAP)升高与心肺复苏后功能预后不良相关
该前瞻性研究纳入100例心脏骤停复苏后患者,在复苏后48小时(容忍区间±12小时)采集血样,检测血清GFAP与NSE水平,主要终点为4周时改良格拉斯哥结局量表评分,低于4分定义为功能预后不良。预后不良组(n=61)GFAP中位数0.03 μg/L(四分位距0.01-0.07 μg/L),预后良好组(n=39)为0.02 μg/L(0.01-0.03 μg/L),p=0.014。GFAP预测预后不良的敏感度60.7%、特异度66.7%;所有GFAP>0.08 μg/L者均预后不良;GFAP>3 μg/L者均有严重脑损伤影像学表现。NSE预测预后不良的敏感度44.3%、特异度100.0%。多因素回归显示GFAP、NSE与Karnofsky指数均为结局的独立预测因子。
要点
- 复苏后48小时(±12小时)血清GFAP>0.08 μg/L者全部(100%)预后不良,可作为床旁高危识别阈值。
- GFAP>3 μg/L者均出现严重脑损伤的脑影像学表现,提示需重点评估神经损伤。
- GFAP预测预后不良敏感度60.7%、特异度66.7%;NSE敏感度44.3%、特异度100.0%,两者释放模式不同。
- 多因素回归显示GFAP、NSE与Karnofsky指数均为复苏后结局的独立预测因子,两者独立贡献于结局预测。
- 预后不良组GFAP中位数0.03 μg/L(0.01-0.07 μg/L)高于预后良好组0.02 μg/L(0.01-0.03 μg/L),p=0.014。
适用人群与场景
- 心脏骤停后心肺复苏成功、于复苏后48小时(容忍区间±12小时)纳入的前瞻性研究人群,共100例。
- 主要终点为4周时改良格拉斯哥结局量表评分,低于4分定义为功能预后不良。
诊断标准与关键阈值
- 功能预后不良定义:4周时改良格拉斯哥结局量表评分低于4分。
- GFAP预测预后不良的阈值参考:GFAP>0.08 μg/L者全部预后不良;GFAP>3 μg/L者均有严重脑损伤的脑影像学表现。
红旗征与不能漏的情况
- 复苏后48小时血清GFAP>0.08 μg/L提示预后不良(本研究中该水平以上者全部预后不良)。
- 血清GFAP>3 μg/L者均存在严重脑损伤的脑影像学表现。
研究设计与关键结果
- 前瞻性研究纳入100例心脏骤停复苏后48小时(±12小时)患者,采集血清检测GFAP与NSE,主要终点为4周改良格拉斯哥结局量表评分(低于4分为预后不良)。
- 预后不良组(n=61)GFAP中位数0.03 μg/L(四分位距0.01-0.07 μg/L),预后良好组(n=39)0.02 μg/L(0.01-0.03 μg/L),p=0.014。
- GFAP预测预后不良的敏感度60.7%、特异度66.7%;NSE敏感度44.3%、特异度100.0%。
- 所有GFAP>0.08 μg/L者均预后不良;GFAP>3 μg/L者均有严重脑损伤的脑影像学表现。
- 多因素回归分析显示GFAP、NSE与Karnofsky指数均为结局的独立预测因子。
证据类型、等级与局限
- 证据类型:前瞻性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 复苏后48小时(±12小时)可检测血清GFAP与NSE,两者释放模式不同,均独立贡献于复苏后结局预测。
- GFAP>0.08 μg/L者在本研究中全部预后不良,GFAP>3 μg/L者均有严重脑损伤影像学表现,可据此识别需重点神经评估的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The neurological prognosis of patients after cardiopulmonary resuscitation (CPR) is difficult to assess. GFAP is an astrocytic intermediate filament protein released into bloodstream in case of cell death. We performed a prospective study aiming to compare the predictive potential of GFAP after resuscitation to the more widely used biomarker neuron-specific enolase (NSE).
METHODS: One hundred patients were included at 48 h (tolerance interval ±12 h) after cardiac arrest. A serum sample was collected immediately after study inclusion. We determined serum levels of GFAP and NSE by means of immunoassays. Primary outcome was the modified Glasgow outcome scale at 4 weeks. Values below four were considered as a poor functional outcome.
RESULTS: Median GFAP levels in poor outcome (n = 61) and good outcome (n = 39) patients were 0.03 μg/L (interquartile range 0.01-0.07 μg/L) and 0.02 μg/L (0.01-0.03 μg/L; p = 0.014), respectively. GFAP revealed a sensitivity of 60.7% and a specificity of 66.7% to predict a poor functional outcome. All patients having a GFAP level >0.08 µg/L had a poor functional outcome. For NSE, sensitivity was 44.3% and specificity was 100.0% for predicting a poor outcome. Multivariate regression analysis revealed GFAP, NSE, and the Karnofsky index to be independent predictors of outcome.
CONCLUSIONS: The release patterns of GFAP and NSE after CPR show differences. GFAP levels above 0.08 µg/L were associated with a poor outcome in all cases, and patients with strongly elevated values (>3 µg/L) consistently had severe brain damage on brain imaging. Both biomarkers independently contribute to outcome prediction after CPR.
参考来源
- Helwig K, Seeger F, Hölschermann H, et al. Elevated Serum Glial Fibrillary Acidic Protein (GFAP) is Associated with Poor Functional Outcome After Cardiopulmonary Resuscitation. Neurocrit Care. 2017. PMID: 28054291. doi:10.1007/s12028-016-0371-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。